All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found one translation.
| Name | Current message text |
|---|---|
| h English (en) | {| |- | [[File:Jänne, Pasi article.jpg|200px|left]] || :Pasi A. Jänne, M.D., Ph.D.Exit Disclaimer :Title: Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science :Institution: Dana-Farber Cancer InstituteExit Disclaimer :Research: Genotype directed precision therapies to combat EGFR mutant or ALK rearranged non- small cell lung cancer show favorable response rates and progression free survival compared to chemotherapy. Significant improvements in treatment using precision therapies involve using combination therapies. Jänne will develop combination therapies using dual targeting of EGFR, vertical pathway inhibition and parallel pathway inhibition. He will focus on improving therapies for EGFR inhibitor naïve cancers. The research will inform preclinical approaches to refine treatments and make improvements in the outcome of EGFR mutant and other lung cancer patients. |} |
